Why did Novo Nordisk stock drop today?

Shares fell after management guided 2026 revenue down 5% to 13% and flagged pressure from U.S. Wegovy price cuts. Sentiment worsened as Hims announced cheaper compounded semaglutide pills, raising competition and margin concerns. Elevated volume and technical overbought signals added to volatility for EUR-based investors.

What do Wegovy price cuts mean for profitability?

Wegovy price cuts reduce U.S. net pricing and raise rebate intensity, which can compress gross and operating margins. Novo must offset this with higher volumes, mix, and efficiency. Investors should watch updated margin guidance, payor coverage trends, and any supply improvements that support sustained prescription growth.

Is the Hims Wegovy copy legal and a real threat?

Compounded drugs can be permitted under specific conditions but are not the same as FDA-approved brands. Novo is pursuing legal and regulatory actions to limit distribution it sees as improper. If compounding access persists, lower prices could siphon demand, pressuring Novo’s market share and pricing power.

What should German investors monitor next?

Track guidance revisions, regulatory developments on compounded semaglutide, and the 6 May 2026 earnings call for margin and cash flow detail. Watch EUR versus USD moves, U.S. payer coverage for GLP-1 drugs, and competitor pricing from Eli Lilly. Manage exposure with staged entries and clear stop levels.

How do valuation and analyst views look now?

Novo trades near 12.4 times TTM earnings with a price-to-sales around 3.9 and strong net margins. Street views skew Hold with a mix of Buy and Sell ratings, while some scoring models lean Buy. Future pricing clarity and volume trends will drive whether multiples expand or compress.

Global Market Insights

NVO Stock Today: February 6 – Price Cuts, Copycat Fight Hit Shares

ByDanny Kontos February 6, 2026February 6, 2026

Novo Nordisk stock slid after management issued 2026 revenue guidance for a 5% to 13% decline tied to U.S. Wegovy price cuts and rising semaglutide competition. Fresh pressure came as Hims Wegovy copy plans surfaced through cheaper compounded pills, prompting legal and regulatory pushback from Novo. For German investors, this mix points to margin risk and share volatility. We break down catalysts, valuation, and the technical picture, and outline clear next steps while noting currency exposure for EUR-based portfolios.